Pharma BD Deal Intelligence
A $30.5B acquisition that transformed Abbott from a pharmaceutical company into a medtech powerhouse. St. Jude's cardiac rhythm management, neuromodulation, and structural heart businesses complemented Abbott's diagnostics and vascular platforms after the AbbVie separation.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Abbott acquired St. Jude Medical for $30.5B for medical devices.
FTC puts conditions on Abbott Laboratories proposed $25 billion acquisition of rival medical device maker St. Jude Medical, requiring divestitures in…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Abbott acquired St. Jude Medical for $30.5B for medical devices.
$15.0B Global CRM Market (2016)
Abbott acquired St. Jude Medical for $25B + $5.5B debt in 2017. Led in CRM, EP mapping, neuromodulation.
Competed with Medtronic, Boston Scientific. EnSite market-leading in EP. Combined with Abbott vascular and MitraClip.
Abbott announces agreement to acquire St. Jude Medical for approximately $25B in cash and stock, combining coronary intervention strength with electrophysiology and neuromodulation.
FTC clears Abbott-St. Jude deal conditioned on divesting St. Jude's vascular closure devices (Angio-Seal) and Abbott's steerable sheaths (Vado) to Terumo Corporation.
Abbott Laboratories completes $25B acquisition of St. Jude Medical, establishing Abbott as a leader across the $30B cardiovascular device market with combined CV sales of ~$8.7B.
Abbott targets $500M in annual pre-tax synergies by 2020 from the St. Jude combination, including sales synergies from cross-selling and operational efficiencies across manufacturing.
Abbott holds #1 or #2 positions across large cardiovascular device markets including electrophysiology, heart failure, structural heart, and chronic pain management.
Abbott reports total 2019 revenue of ~$31.9B with strong growth in medical devices segment, driven by St. Jude cardiovascular and neuromodulation products alongside diagnostics.
St. Jude acquisition transformed Abbott into a medtech powerhouse. Combined CV portfolio achieved #1-2 positions, synergy targets met, and device segment became Abbott's growth engine.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / St. Jude Medical (this deal) | 2016 | $30.5B | 82 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2016 deals · Abbott Laboratories deals · Cardiovascular deals